#PCVX hashtag - Bluesky

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine (OPUS-2) and Expects to Initiate Phase 3 Study in Adults Previously Vaccinated with Pneumococcal Vaccines (OPUS-3) in First Quarter of 2026

2 months ago

#PCVX Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

www.stocktitan.net/news/PCVX/vaxcyte-advanc...

0 0 0 0

InsiderFinance

@insiderfinance.com

2 months ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CHKP, #PCVX, #BIDU, #ATRC, #BLDP

#OptionFlow #OptionsTrading #Trading

0 0 0 0

Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive (PCV21) and Prevnar 20

3 months ago

#PCVX Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

www.stocktitan.net/news/PCVX/vaxcyte-doses-...

0 0 0 0

Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study Vaxcyte (NASDAQ: PCVX) reported Q3 2025 results and a business update on Nov 4, 2025. The company reported $2.67B in cash, cash equivalents and investments as of Sept 30, 2025, and expects this to fund the current operating plan into mid‑2028. Final VAX‑24 infant Phase 2 data were consistent with prior positive interim results, showing robust, dose‑dependent IgG and OPA responses and meeting target non‑inferiority criteria for most serotypes. The modified VAX‑31 infant Phase 2 advanced to its third stage (~900 infants). VAX‑31 adult Phase 3 is expected to start in Dec 2025 with topline data in 2026. Company announced up to $1B U.S. fill‑finish commitment and named Mike Mullette CCO.

4 months ago

#PCVX Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study

www.stocktitan.net/news/PCVX/vaxcyte-report...

0 0 0 0

92% Disease Coverage: Vaxcyte's VAX-31 Could Become Broadest Pneumococcal Vaccine for Infants Vaxcyte's VAX-31 Phase 2 trial advances with optimized dosing (4.4mcg/3.3mcg) in 900-patient study. Vaccine targets 92% IPD coverage in children under 5. Data expected H1 2027.

6 months ago

#PCVX Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose

www.stocktitan.net/news/PCVX/vaxcyte-advanc...

0 0 0 0

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update Vaxcyte (PCVX) reported Q1 2025 financial results and significant progress in its pneumococcal conjugate vaccine (PCV) pipeline. The company announced positive Phase 2 results for VAX-24 in healthy infants, showing favorable safety and immunogenicity data. Vaxcyte has initiated the final stage of VAX-31 infant Phase 2 study, with topline data expected mid-2026. The company plans to begin VAX-31 adult Phase 3 pivotal trials by mid-2025. They also introduced VAX-XL, their third-generation PCV candidate. Financially, Vaxcyte maintains a strong position with $2.95 billion in cash and investments as of March 31, 2025. Q1 results showed R&D expenses of $148.1M (up from $94.6M YoY) and a net loss of $140.7M (compared to $95.0M YoY). The company continues construction of its commercial manufacturing suite at Lonza, with completion expected by early 2026.

10 months ago

#PCVX Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/PCVX/vaxcyte-report...

0 0 0 0

11 months ago

NEWS: ( NASDAQ: #PCVX ) Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

0 0 0 0

Breakthrough: Vaxcyte's New Vaccine Shows Promise in Phase 2 Infant Trial New clinical data reveals VAX-24 vaccine achieves positive results in 20 of 24 serotypes. Mid-dose selected for potential Phase 3 advancement. Full analysis inside.

11 months ago

#PCVX Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

www.stocktitan.net/news/PCVX/vaxcyte-announ...

0 0 0 0

Can Vaxcyte's $3.1B War Chest Revolutionize the Pneumococcal Vaccine Market? Strong financial position with $3.1B cash despite increased R&D spending. VAX-31 earned FDA Breakthrough Therapy Designation with Phase 3 trials starting mid-2025.

1 year ago

#PCVX Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/PCVX/vaxcyte-report...

0 0 0 0

Revolutionary Pneumococcal Vaccine Shows Promise: Vaxcyte's VAX-31 Hits Major Clinical Milestone Vaxcyte's 31-valent pneumococcal vaccine progresses to Phase 2 Stage 2, demonstrating strong safety profile. Aims to protect against 94% of pneumococcal disease in young children.

1 year ago

#PCVX Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

www.stocktitan.net/news/PCVX/vaxcyte-advanc...

0 0 0 0

Vaxcyte Launches Phase 2 Trial for Advanced Pneumococcal Vaccine with 94% Coverage | PCVX Stock News Vaxcyte initiates Phase 2 study of VAX-31, a 31-valent pneumococcal vaccine offering potential 94% disease coverage in young children. Key data expected mid-2026.

1 year ago

#PCVX Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

#news #stocks #StockMarket

www.stocktitan.net/news/PCVX/vaxcyte-initia...

0 0 0 0

1 year ago

NEWS: ( NASDAQ: #PCVX ) Buy Recommendation Issued On PCVX By Needham

#StockMarket #News

1 0 0 0

1 year ago

JUST IN: ( NASDAQ: #PCVX ) Buy Recommendation Issued On PCVX By BTIG

#StockMarket #News

1 0 0 0

1 year ago

Just In: ( NASDAQ: #PCVX ) PCVX Price Target Alert: $129.00. Issued by Jefferies

#StockMarket #News

1 0 0 0

1 year ago

NEWS: ( NASDAQ: #PCVX ) Buy Recommendation Issued On PCVX By Jefferies

#StockMarket #News

1 0 0 0

1 year ago

News; ( NASDAQ: #PCVX ) Vaxcyte stock soars 35% on promising VAX-31 vaccine trial results

#StockMarket #News

1 0 1 0